Candida auris and COVID-19: A health threatening combination

Since its first emergence in December 2019, due to its fast distribution throughout the world, SARS-COV-2 become a global concern. With the extremely increased number of hospitalized patients, this situation provided a potential basis for the transmission of nosocomial infections. Candida auris is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Khojasteh, Shaghayegh, Jafarzdeh, Jalal, Hosseini, Seyed Abdollah, Haghani, Iman, Turki, Habibollah, Aghaei Gharehbolagh, Sanaz, Abastabar, Mahdi, Mahmoudi, Shahram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Society of Medical Mycology 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084486/
https://www.ncbi.nlm.nih.gov/pubmed/37051551
http://dx.doi.org/10.18502/cmm.8.3.11211
Descripción
Sumario:Since its first emergence in December 2019, due to its fast distribution throughout the world, SARS-COV-2 become a global concern. With the extremely increased number of hospitalized patients, this situation provided a potential basis for the transmission of nosocomial infections. Candida auris is a multidrug-resistant pathogen with improved transmission dynamics and resistance traits. During the worldwide spread of COVID-19, cases or outbreaks of C. auris colonization or infection have been reported. Resistance to antifungal drugs has been observed in the causative agents of the majority of such cases. The focus in this review is on COVID-19-associated C. auris infections (case studies/outbreaks) and the pandemic's potential effect on antifungal drug resistance.

Ejemplares similares